Purpose of trial
The aim of this trial is to find out if AZD6738 could be a safe and effective treatment for people with CLL who have had previous treatment but do not have any other standard treatment options. If you have already had treatments such as ibrutinib and venetoclax, this trial might give you a new treatment option.
AZD6738 is being tested alone and together with another drug, acalabrutinib.
AZD6738 is a cell signal blocker. It works by blocking signals that tell cancer cells to repair themselves. This can make the cancer cells die.
Acalabrutinib is a cell signal blocker that works in a similar way to ibrutinib, which is a drug already available for some people with lymphoma. Acalabrutinib is more selective than ibrutinib at targeting specific cells. It is hoped that acalabrutinib will therefore have a greater effect on cancer cells and cause fewer side effects than ibrutinib.
There are two treatment groups in this trial:
- AZD6738 alone
- AZD6738 with acalabrutinib.
You are put into one of the groups at random. You cannot choose which group you are in. You are given information about all of the treatments in this trial.
You take both drugs orally (by mouth) as tablets or capsules. You continue to take treatment for as long as it is benefitting you.
Who can enter
Your consultant can give you advice on whether this trial might be suitable for you.
Around 62 people are needed for this trial.
You may be able to enter if:
- You have CLL.
- You have received previous treatment for your CLL but it needs treatment again.
- Your CLL is at high risk of getting worse.
- You do not have any other standard treatment options.
- Your blood and other health test results are satisfactory.
- You are 18 or over.
You won’t be able to enter if:
- You have ataxia telangiectasia (a condition where your immune system doesn’t work properly).
- You have had a similar drug to AZD6738 before.
- You have HIV.
- You are pregnant or breastfeeding.
- You have any other problems that your doctor thinks might make it unsafe for you to have the study treatment.
More information about this trial is available at clinicaltrials.gov.